Moxisylyte

Moxisylyte
Clinical data
Other names	Thymoxamine
AHFS/Drugs.com	International Drug Names
ATC code	G04BE06 (WHO) C04AX10 (WHO);
Identifiers
	IUPAC name 4-[2-(Dimethylamino)ethoxy]-5-isopropyl-2-methylphenyl acetate;
CAS Number	54-32-0 ;
PubChem CID	4260;
DrugBank	DB09205 ;
ChemSpider	4110;
UNII	PW8QYA7KI0;
KEGG	D08239 ;
CompTox Dashboard (EPA)	DTXSID4023339 ;
ECHA InfoCard	100.000.186
Chemical and physical data
Formula	C16H25NO3
Molar mass	279.380 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C;
	InChI InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3; Key:VRYMTAVOXVTQEF-UHFFFAOYSA-N;
	(verify)

Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction.^[1] It is an α₁-adrenergic antagonist.^[2] In the United Kingdom, Moxisylyte is marketed as Opilon (Archimedes Pharma UK Ltd) and is used for the short-term treatment of primary Raynaud's syndrome. This is a condition where the fingers and toes become discoloured and is triggered by responses to cold, or emotional distress. Opilon tablets help by improving blood circulation to the extremities.^[3]^[4]